Scientists dive deep into Asthma's inner workings
NCT ID NCT06105710
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study aims to understand why people with asthma produce excess mucus. Researchers will collect airway cells from 24 volunteers (some with asthma, some healthy) using a thin tube passed into the lungs. By comparing the cells' genetic activity, they hope to pinpoint key molecules involved in mucus production. This is a knowledge-gathering study, not a treatment trial.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this study could reveal new biological targets for future asthma treatments.
- What could go wrong
- This is a small, early-stage observational study (24 participants) focused on understanding mechanisms, not testing a therapy. Results may not directly lead to treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jul 2024
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Healthy and asthmatic participants recruited from community advertising
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy Controls 1. Male and female subjects between the ages of 18 and 70 years 2. Ability to provide written informed consent and ability to comply with the requirements of the study 3. No hyperreactivity to methacholine (PC20 FEV1 Methacholine \>16 mg/mL) 4. No history of allergic rhinitis/seasonal allergies * Asthmatics 1. Male and female subjects between the ages of 18 and 70 years 2. Ability to provide written informed consent and ability to comply with the requirements of the study 3. History of asthma 4. No use of oral or inhaled corticosteroids for the treatment of asthma during the past 6 weeks 5. Hyperreactivity to methacholine (PC20 FEV1 Methacholine \< 8 mg/ml) Exclusion Criteria: The same exclusion criteria will apply to both Sub-studies. 1. Current smokers, defined by (a) \>5 cigarettes smoked in past 12 months, and (b) ≤ 8 weeks since last time smoking; or former smokers who have a total smoking history * 10 pack-years 2. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study 3. Subjects with a history of lung disease other than asthma 4. Subjects with a history of prior esophageal hernia surgery 5. Subjects with a history of a medical disease, which in the opinion of the Investigator may put the subject at extra risk from study-related procedures or because the disease may influence the results of the study 6. Current participation in an investigational drug trial Prohibited Medications and Treatments The following medications are prohibited during the study and must be discontinued prior to enrollment for the amount of time specified below. 1. Astemizole: 12 weeks 2. Steroids (oral, inhaled or nasal): 6 weeks 3. Nedocromil sodium, sodium cromoglycate: 4 weeks 4. Long-acting methylxantines: 2 days 5. Short-acting methylxantines: 12 hours 6. Montelukast: 7 days 7. Zafirlukast: 7 days 8. Salmeterol: 2 days 9. Omalizumab: 6 months Medications to be withheld prior to bronchoscopy: Aspirin or Non- steroidal anti-inflammatory agents (NSAIDs) for 2 days Medications to be withheld before each clinic visit: Short-acting bronchodilators (e.g. Albuterol) for 6 hours; Short-acting anti- cholinergics (e.g. Atrovent, Combivent) for 8 hours; and antihistamines (e.g. Benadryl, Claritin) for 3 days.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Asthma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of California, San Francisco
RECRUITINGSan Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Asthma's hidden switch: scientists hunt for calcium channels in Kids' immune cells
- Can a simple breath test cut asthma Flare-Ups?
- Breathing tests face off: can extra lung measurements improve asthma diagnosis?
- The carbon label on your inhaler: can it sway a Doctor's choice?
- Six biologics put to the test in Real-World asthma and COPD care
- Can a digital program help teens with chronic illnesses move to adult care?